Mabwell (Shanghai) Bioscience 관리

관리 기준 확인 2/4

Mabwell (Shanghai) Bioscience CEO는 Datao Liu, Jun2020 에 임명되었습니다 의 임기는 4.42 년입니다. 는 CN¥ 366.18M 가치에 해당하는 회사 주식의 3.78% 직접 소유합니다. 366.18M. 경영진과 이사회의 평균 재임 기간은 각각 4.4 년과 4.4 년입니다.

주요 정보

Datao Liu

최고 경영자

CN¥2.4m

총 보상

CEO 급여 비율	n/a
CEO 임기	4.4yrs
CEO 소유권	3.8%
경영진 평균 재임 기간	4.4yrs
이사회 평균 재임 기간	4.4yrs

최근 관리 업데이트

Recent updates

CEO

Datao Liu (52 yo)

4.4yrs

테뉴어

CN¥2,406,000

보상

Dr. Datao Liu serves as the General Manager and Director of Mabwell (Shanghai) Bioscience Co., Ltd. since June 2020 and serves as it Chief Executive Officer and has been its Chairman since June 2023. He al...

리더십 팀

이름	위치	테뉴어	보상	소유권
Datao Liu	Chairman	4.4yrs	CN¥2.41m	3.78% CN¥ 366.2m
Xin Du	Chief Scientific Officer & President of Maiwei (US)	4.4yrs	CN¥3.14m	데이터 없음
Yinhan Guo	Chief R&D Officer	4.1yrs	CN¥1.93m	데이터 없음
Jinchao Zhang	Deputy General Manager	4.4yrs	CN¥1.59m	1% CN¥ 97.0m
Huiguo Hu	Deputy GM	4.4yrs	CN¥1.58m	데이터 없음
Shu Hai Wang	Deputy General Manager	4.4yrs	CN¥1.58m	0.10% CN¥ 9.7m
Xi Chen	Deputy General Manager	3.8yrs	CN¥1.58m	데이터 없음
Han Li	Deputy General Manager	4.2yrs	CN¥1.94m	데이터 없음
Weiyi Dong	Deputy General Manager	4.4yrs	CN¥961.20k	데이터 없음
Hua Ni	Deputy General Manager	4.2yrs	CN¥1.42m	데이터 없음
Hai Wu	President of R&D	less than a year	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 688062 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Datao Liu	Chairman	4.4yrs	CN¥2.41m	3.78% CN¥ 366.2m
Huiguo Hu	Deputy GM	3.5yrs	CN¥1.58m	데이터 없음
Chunshan Tang	Director	4.4yrs	데이터 없음	35.18% CN¥ 3.4b
Ning Xie	Director	4.4yrs	CN¥1.55m	1.64% CN¥ 159.3m
Bailing Li	Independent Director	4.1yrs	CN¥180.00k	데이터 없음
Qian Zhao	Independent Director	4.1yrs	CN¥180.00k	데이터 없음
Qing Xu	Independent Director	4.1yrs	CN¥180.00k	데이터 없음
Yongqi Guo	Director	4.4yrs	데이터 없음	데이터 없음
Jian Chu	Chairman of the Supervisory Board	4.4yrs	데이터 없음	데이터 없음
Xianghong Huang	Employee Representative Supervisor	4.4yrs	데이터 없음	데이터 없음
Yue Yin	Supervisor	4.4yrs	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: 688062 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

Mabwell (Shanghai) Bioscience 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Insufficient new directors

High number of new and inexperienced directors

Recent updates

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

New major risk - Share price stability

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA

New minor risk - Share price stability

FDA Grants Orphan Drug Designation to 7MW3711

FDA Grants Fast Track Designation to Mabwell's 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Mabwell Announces 9MW2821 Clinical Data

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821

First quarter 2024 earnings released: CN¥0.51 loss per share (vs CN¥0.60 loss in 1Q 2023)

Full year 2023 earnings released: CN¥2.64 loss per share (vs CN¥2.44 loss in FY 2022)

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting

Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology

Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Fiscal Year 2023 Results on Apr 09, 2024

National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA

Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial

Insufficient new directors

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

Second quarter 2023 earnings released: CN¥0.43 loss per share (vs CN¥0.51 loss in 2Q 2022)

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND

Full year 2022 earnings released: CN¥2.44 loss per share (vs CN¥2.57 loss in FY 2021)

High number of new and inexperienced directors

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령